Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-2019
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis ; volume:24 ; number:1 ; day:18 ; month:11 ; year:2021 ; pages:91 ; date:1.2022
Pediatric drugs ; 24, Heft 1 (18.11.2021), 91, 1.2022
- Urheber
-
Blair, Hannah A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40272-021-00483-x
- URN
-
urn:nbn:de:101:1-2022042407073250802920
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Blair, Hannah A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis
Secukinumab (Plaque-Psoriasis) : Addendum zum Auftrag A17-08
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data
Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry
Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis
Secukinumab (Plaque-Psoriasis) : Addendum zum Auftrag A17-08
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data
Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry
Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis
Secukinumab (Plaque-Psoriasis) : Addendum zum Auftrag A17-08
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data
Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry